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Abstract 
Gene therapy represents a feasible strategy to treat inherited monogenic diseases and intramuscular 
(i.m.) injection of recombinant adeno-associated viral (AAV) vector is now recognized as a 
convenient and safe method of gene transfer. However, this approach is hampered by immune 
responses directed against the vector and against the transgenic protein. We used here to reproduce 
this situation a mouse model where robust immune responses are induced following injection of an 
AAV vector coding for an immunogenic transgenic protein. We show that prophylactic oral 
administration of the immunogenic protein before AAV-mediated gene transfer completely 
prevented antibody formation and cytotoxic CD8+ T cell response. Consistently, prophylactic oral-
tolerization considerably improved long-term transgene persistence and expression. 
Mechanistically, inhibition of the cytotoxic immune response involved abortive proliferation of 
antigen-specific cytotoxic CD8+ T cells, up-regulation of the PD-1 immunoregulatory molecule, 
down-regulation of the Bcl-2 anti-apoptotic factor, and their deletion in the context of AAV-
mediated gene transfer. Hence, gene therapy may represent an ideal situation where oral-tolerization 
can be adopted before or at the same time as vector injection to efficiently prevent deleterious 
immune responses directed against the transgenic protein. 
 
Keywords: gene therapy, AAV vectors, immune responses, oral tolerance, transgenic proteins, 
transgene persistence. 
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Introduction 
The use of viral-derived vectors in gene therapy settings represents a promising strategy to 
treat monogenic diseases or to induce the expression of a given secreted therapeutic transgenic 
protein in vivo 1, 2. Recombinant AAV vectors represent a safe and efficient way to achieve in vivo 
gene transfer and, depending on the serotype, can be used to transduce different target tissues 3, 4. 
AAV vectors also demonstrated several advantages over other viral-derived vectors, as their lower 
immunogenicity, their ability to transduce non-dividing cells, and their lower risk to induce 
insertional mutagenesis 1-5. 
 
AAV-mediated gene transfer and long-term transgene expression has been achieved in 
several preclinical animal models as well as in clinical trials where it was demonstrated to be safe 
and effective 6-8. However, AAV-mediated gene transfer triggers immune responses directed against 
the viral capsid proteins and/or against the transgenic proteins 5, 7, 9-14.  Activation of cytotoxic CD8+ 
T cells mediates the destruction of transduced cells and loss of transgene expression 7, 9, 14-16 and 
humoral immunity generates neutralizing antibodies 5, 16-19. To date, administration of 
immunosuppressive drugs and/or careful patients selection to avoid immune responses directed 
notably against the transgenic protein represent the only approaches to circumvent this limitation 7, 
11, 18, 20-24. Yet, immune responses have been observed in clinical trials despite the use of 
immunosuppressive drugs 18, 21. Hence, strategies aiming to circumvent immune responses 
following AAV vectors injection should greatly enhance long term transgene expression and may 
broaden the number of patient electable for gene therapy 10, 11. In our study, we evaluated an 
alternative approach to promote antigen-specific oral-tolerization instead of systemic immune 
suppression.  
 
Oral tolerance is characterized by a specific inhibition of the immune responses directed 
against defined antigens administered by the oral route. Therefore, it has the advantage over drug-
based immunosuppression to be antigen-specific and long-lasting. Tolerance induction represents 
the “default” response of the intestinal immune system. Intestinal dendritic cells (DCs), located in 
the lamina propria and mesenteric lymph nodes (MLNs), have been implicated in the uptake of 
orally derived antigens and in their tolerogenic presentation to T cells 25-30. Several mechanisms 
have been identified that could account for the induction of oral tolerance as anergy and/or deletion 
of antigen-specific T cells 31, 32 or induction of regulatory T cells (Tregs) 25, 33.  
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Encouraging results have been obtained in clinical trials using oral tolerance to treat allergies 
while partial clinical responses, limited to particular subsets of individual, were observed in the 
context of autoimmune diseases. This suggests that the efficacy of oral-tolerization might depend 
on the clinical situation and on the specific immune status of each patient 34, 35. One explanation 
may reside in the difficulty to tolerize secondary/memory immune responses suggesting that oral-
tolerization may be beneficial in prophylactic rather than curative scenario 36. Interestingly, gene 
therapy may offer such clinical situations by providing the possibility to tolerize individuals before 
vector injection. 
 
 We tested in the present study the effects of oral-tolerization in an animal model of AAV-
mediated gene transfer. For that, the protein coded by the vector was first orally administrated for 7 
days prior to AAV-mediated gene transfer. To stringently evaluate the tolerization capacity of this 
protocol, we chose here as a protein model the highly immunogenic ovalbumin (Ova) antigen and 
the i.m. route. We previously showed that i.m. injection of AAV-Ova induces prominent humoral 
and cellular immune responses that are associated with rapid loss of transgene expression 37, 38. We 
provide here the first proof-of principle that oral-tolerization prior to AAV-mediated gene transfer 
completely abrogates humoral and cellular immune responses directed against a soluble 
immunogenic transgenic protein. This was associated with long-term transgene expression and with 
the maintenance of the secreted transgenic protein in the circulation of tolerized animals. 
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Results 
 
Oral-tolerization prevents immune responses directed against the transgenic protein  
Intramuscular administration of AAV vectors can lead to a robust immune response that 
correlates with the elimination of the transduced cells and with the disappearance of the transgenic 
protein 37, 39. We investigated here, in an animal model, the efficiency of oral-tolerization to prevent 
the immune response directed against the transgenic protein. For that, mice were orally-tolerized 
with the model protein Ovalbumin (Ova), given at 1% in the drinking water, prior to i.m. 
administration of AAV-Ova at day 0. Immune responses were then monitored over time from days 
14 to 80 (Fig. 1a). In untolerized control animals, up to 18% of circulating CD8+ recognized Ova 
14 days post AAV-Ova transduction. In contrast, orally-tolerized mice displayed little if any cellular 
immune responses (Fig. 1b, c). Ova-specific CD4+ and CD8+ immune responses were also 
undetectable by the more sensitive ELISpot assay in orally-tolerized mice at day 80 (Fig. 1f, g). 
Similarly, oral-tolerization significantly prevented the formation of anti-Ova IgG antibodies (Fig. 
1d, e). Of note, this oral-tolerization protocol completely blocked immune responses irrespectively 
of the administrated dose of AAV-Ova, i.e. 3.5x109, 5×1010 or 1011 vg (supplemental Fig. 1a-c). 
Also, oral feeding for only 5 days (supplemental Fig. 1d-f), or using a 10-fold lower concentration 
of Ova (i.e. 0.1%) (Supplemental Fig. 1g), similarly resulted in complete prevention of immune 
responses, suggesting that robust tolerization mechanisms are induced following oral feeding. 
 
 We then evaluated the capacity of our tolerization protocol to inhibit immune responses in 
less favorable conditions resulting from the use of incompletely purified AAV-preparations or from 
the use of self-complementary AAV vectors (scAAV). Indeed, both conditions are associated with 
the triggering of TLR receptors and activation of innate immune cells. To mimic these situations, 
we co-injected our AAV-Ova vector with contaminating CpG-ODNs, a potent TLR9 agonist. Our 
results demonstrate that, even in this more immunogenic situation, oral-tolerization prevented 
cellular and humoral immune responses directed against Ova and improved its persistence in the 
circulation (Supplemental Fig. 2).  
 
Next, we investigated the functionality of the cytotoxic T cells generated upon AAV-Ova 
transduction using a well-characterized CD8+-dependent anti-tumor response in vivo 38, 40. For that, 
Ova-bearing EG7 cells were injected s.c. in tolerized or control mice 14 days after AAV-Ova 
injection and tumor growth was monitored overtime. Results showed that virtually all control mice 
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rejected Ova-bearing tumor cells (Fig. 1h, i). In contrast, all tolerized mice developed tumors within 
the first 30 days after EG7 inoculation in agreement with the absence of functional anti-Ova 
cytotoxic T cells response in tolerized mice.  
 
CD8+ T cells do not infiltrate muscles in tolerized mice 
We next investigated the presence of mononuclear cells infiltration in transduced muscles 
sections. For that, gastrocnemius were harvested 21, 29 or 46 days after gene transfer for histological 
analyses. Hematoxylin and eosin staining revealed at day 21 and 29 conspicuous mononuclear cell 
infiltration and myofiber necrosis/regeneration evidenced by the presence of centronucleated fibers 
in muscle sections of untolerized mice (Fig. 2a, b). Immunofluorescence confirmed the presence of 
cytotoxic T cells expressing both CD3 and CD8 that surrounded muscle fibers (Fig. 2g, h). At the 
latest time point analyzed, histological muscle structure tended to normalize suggesting termination 
of the immune response and almost complete muscle regeneration (Fig. 2c). In contrast, little if any 
mononuclear cell infiltration was detected in orally-tolerized mice (Fig. 2d-f) and CD8+ cytotoxic 
T cells were virtually absent at all analyzed time points (Fig. 2j-l). Only CD3-CD8+ cells, possibly 
corresponding to DCs, were sparsely detected. Thus, oral-tolerization prior to AAV-mediated gene 
transfer protects transduced muscle fibers from CD8+ cytotoxic T cells. 
 
Oral-tolerization favors transgene long-term expression 
We next examined whether the control of immune responses was associated with the long-
term persistence of the transgene. For that, the relative abundance of DNA and mRNA coding for 
Ova were quantify in transduced muscles 80 days after AAV-Ova injection. As anticipated, we 
observed significant higher copy numbers of the transgene and of its corresponding mRNA, in 
muscle samples of tolerized mice (Fig. 3a, b). Concordantly, quantification of Ova in serum 
confirmed the stable expression of Ova in tolerized mice while Ova was under the limit of detection 
in control mice (Fig. 3c). Hence, these results show that oral-tolerization sustains transgene 
persistence and expression, and allows long-term maintenance of the secreted transgenic protein.  
 
Oral-tolerization induces abortive proliferation of adoptively transferred Ova-specific CD8+ 
T cells 
To investigate the mechanisms involved, we first analyzed the cell subsets present in the 
MLNs. No difference was found in the frequencies nor in the phenotypes of the analyzed subsets, 
that included Tregs, Bregs and DCs (Supplemental Fig. 3). Also, depletion/inactivation of the vast 
majority of CD4+Foxp3+ Tregs at the end of the oral-tolerization protocol was not sufficient to 
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abrogate the induced tolerance (Supplemental Fig. 4). We next investigated the possible induction 
of anergy and/or deletion of antigen-specific T cells. As anergy can be breached by pro-
inflammatory infections, we next infected orally-tolerized mice with a replicative Listeria 
monocytogenes strain expressing Ova (Lm-Ova). In contrast to what we observed following 
injection of the replication-defective AAV-Ova (Fig. 1), mice responded well to Lm-Ova (Fig. 4a, 
b), indicating that Ova-specific T cells are still present and are anergized rather than deleted during 
the initial step of oral-tolerization.  
 
To study more precisely the fate of anti-Ova CD8+ T cells, Ova-specific CD8+ T cells from 
TCR-Tg OT-I mice harboring the CD45.1 congenic marker (OT-I CD45.1+ cells) were adoptively 
transferred into CD45.2 recipients. Transferred cells were significantly more abundant in tolerized 
mice than in control animals and expressed the CD44 activation marker (Fig. 4c, d). Labeling with 
a fluorescent dye revealed that adoptively transferred OT-I CD45.1+ cells indeed proliferated in the 
MLNs of tolerized mice (Fig. 4e), but also acquired expression of the PD-1 exhaustion/anergic 
marker alongside cell division (Fig. 4f). One third of transferred cells also acquired expression of 
CD73, a regulatory molecule involved in anergy 41 (Fig. 4g, h). Finally, as anergic T cell tend to die 
by apoptosis 42, we further analyzed the intracellular level of the anti-apoptotic factor Bcl-2 and 
observed that transferred cells displayed reduced levels of Bcl-2 (Fig. 4g, h). Taken together, these 
results suggest that Ova-specific T cells abortively proliferate in the MLNs upon encounter of their 
nominal antigen brought by the oral route.  
 
Oral-tolerization induces deletion of Ova-specific CD8+ T cells in the context of AAV-mediated 
gene therapy 
We next addressed the fate of antigen-specific cells, not only after oral-tolerization, but also 
following AAV-mediated gene transfer. For that, OT-I CD45.1+ cells were again injected in 
congenic CD45.2 recipient mice and followed after AAV-Ova i.m. injection. While previous 
experiments demonstrated very few transferred CD45.1+ cells in control animals before injection of 
AAV-Ova (Fig. 4c, d), these cells were clearly visible after gene transfer in spleen,  draining lymph 
nodes, and circulation suggesting cell rebound following antigenic stimulation (Fig. 5a, b). In 
contrast, CD45.1+ that were more abundant in tolerized animals before gene transfer (Fig. 4c, d), 
were almost undetectable later in spleen,  draining lymph nodes, and circulation of these animals 
(Fig. 5a, b). Lastly, we enumerated transferred cells to ascertain that CD45.1+ cell percentage 
faithfully reflected their absolute number. The results confirmed that the absolute number of 
antigen-specific CD8+CD45.1+ cells gradually increased in the peripheral lymphoid organs of 
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untolerized mice while, in striking contrast, they completely disappeared from the lymphoid organs 
of tolerized mice (Fig. 5c). Altogether, these data suggest that although antigen-specific CD8+ T 
cells divided during oral-tolerization, they acquired PD-1, down-regulated Bcl-2 survival factor, and 
are finally deleted from the repertoire of tolerized mice upon antigen reencounter in the context of 
AAV-mediated muscle gene transfer.  
 
Prophylactic oral-feeding, but not interventional oral-feeding, prevents immune responses 
elicited by AAV vectors 
 As oral-tolerization has yielded limited success in the treatment of autoimmune diseases, we 
next wondered whether oral-tolerization would be more efficient to prevent, rather than to suppress, 
immune responses. To examine this question, we applied the oral-tolerization protocol to animals 
pre-immunized with CFA/Ova before initiation of oral-tolerization. Results showed that oral-
tolerization was not efficient to prevent immune responses elicited by AAV-Ova transduction in the 
pre-immunized group of mice (Fig. 6a-d). Similar results were obtained with animals pre-
immunized with Lm-Ova to elicit a memory anti-Ova immune response 35 days before the 
administration of the AAV-Ova vector (data not shown).  Thus, oral-tolerization is very efficient to 
prevent primary immune responses elicited by AAV-vectors but not secondary/memory immune 
responses. We next directly compared prophylactic and interventional protocols by initiating 
antigen feeding either before, at the same time, or after vector transduction. Results showed that 
initiation of oral-tolerization at the same time as vector transduction was as effective as its initiation 
7 days before to completely prevent the emergence of the cytotoxic CD8+ T cells response (Fig. 6e). 
However, expression of transgenic protein from single-stranded DNA AAV-vectors is known to 
require at least 7 days in vivo, suggesting that oral-tolerization may still have been initiated in this 
particular situation before the priming of the immune response. Concordantly, when antigen feeding 
was initiated 10 days after vector transduction (i.e., at a time point where immune responses become 
detectable), oral feeding was inefficient to suppress cytotoxic CD8+ T cells response and to improve 
long-term transgene persistence (Fig. 6f, g). Thus, oral-tolerization by antigen feeding is only 
effective when applied before or at the same time as vector transduction, two situations that are still 
fully compatible with the specific clinical context of gene therapy.  
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Discussion 
 
Significant progress has been made in the field of AAV gene therapy to improve efficacy 
and safety of the vectors. One of the main persisting challenges is the better control of adverse 
immune responses to improve long-term expression of the transgene. Indeed, immune responses 
directed against the vector not only compromise transduction efficiency during vector re-injections, 
but also lead to the elimination of transduced cells by capsid-specific cytotoxic CD8+ T cells 9, 12, 43. 
The transgenic protein itself, coded by the vector, also induces immune responses that can impair 
gene transfer efficacy 5, 16. Actual strategies used in clinic to overcome this limitation include 
administration of immunosuppressive drugs and careful selection of the patients presenting the 
lower risk of developing such immune responses notably against the transgenic protein. For 
instance, patients enrolled in hemophilia gene therapy trials were elected based on the nature of their 
genetic mutation (i.e., missense rather that nonsense mutations) and based on their absence of 
immune responses (i.e., inhibitors formation) to protein replacement therapy 20, 22-24. Developing 
strategies to inhibit these immune responses is therefore of major importance, not only to promote 
long-term transgenic protein expression, but also to extend gene therapy to other patients. We 
evaluated here an oral-tolerization strategy to specifically dampen the humoral and cellular immune 
responses directed against the transgenic protein coded by the AAV vector and demonstrated its 
efficacy to improve long-term transgene expression (Fig. 1 and 3).  
 
We used here as a model an AAV-Ova vector to elicit muscle secretion of Ova following its 
intra-muscular administration. This experimental condition mimics clinical situations where the 
transgenic protein is meant to be expressed systemically such as gene therapy of hemophilic patients 
for instance. We chose here a highly immunogenic protein model to generate a stringent model 
where protocols designed to inhibit immune responses can be faithfully evaluated. We used this 
experimental setting to show that prophylactic oral administration of the protein of interest is able 
to completely prevent both humoral (Fig. 1d, e) and cellular immune responses (Fig. 1b, c and f, 
g) induced by AAV-mediated muscle gene transfer. Concordantly, the transgenic Ova protein was 
persistent in the serum until the latest time-points studied (Fig. 3c) as was the corresponding Ova 
mRNA in transduced muscle (Fig. 3a, b). This was in agreement with the absence of cytotoxic 
CD8+ T cells infiltration in the transduced muscles of orally-tolerized mice (Fig. 2d-f and j-l).  
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Regarding the mechanism, we evaluated the potential role of Foxp3+ Tregs in the 
induction/maintenance of tolerance in our model. Using a robust protocol that we developed to 
deplete and inactivate Foxp3+ Tregs, we showed that their depletion/inactivation at the end of the 
oral-tolerization phase was not sufficient to abrogate orally-induced tolerance and to restore cellular 
and humoral immune responses (Supplemental Fig. 4). This suggested, at best, a minor role of 
these cells in our model. However, the role of other described subsets of regulatory T cells cannot 
be excluded. Among the subset that have been previously implicated in oral tolerance, we analyzed 
the proportion CD4+LAG-3+Foxp3- Tr1 cells 44. Indeed, this subset is known to secrete IL-10, a 
well-known immunoregulatory cytokine, and has been previously involved in the induction of oral 
tolerance 45. Our results did not reveal substantial difference in the percentages of 
CD4+LAG-3+Foxp3- found in the mesenteric lymph nodes of tolerized animals as compared to 
control mice nor in their levels of LAG-3 expression (Supplemental Fig. 3i and data not shown). 
Yet, further functional investigations, as well as the study of their antigen-specificity, and their 
numbers in lamina propria or Peyer's patches would be required to formally exclude their 
implication in our model. Th3 cells, characterized by their CD4+LAP+Foxp3- phenotype and by the 
production of TGF-β, represent another regulatory T cell subset that has been associated with oral 
tolerization. Indeed, Th3 cells have been previously demonstrated to be elicited upon oral 
administration of myelin basic protein (MBP) and to prevent the development of autoimmune 
encephalomyelitis in a mouse model 46. As we did not specifically studied this subset, their role 
cannot be excluded in our model. This may possibly be of importance as immunoregulatory 
cytokines akin to IL-10 and/or TGF-β produced by Tr1 and Th3 subsets are known to considerably 
affect the differentiation, survival and functions of CD8+ cytotoxic T cells.  
 
Even if the precise mechanism involved in the regulation of the CD4+ T cell compartment 
still remain to be precisely studied, we provide herein interesting data on the mechanisms involved 
in the regulation of CD8+ T cells compartment by oral tolerization. We show here that adoptively 
transferred antigen-specific CD8+ T cells gradually acquired high levels of PD-1 expression as they 
proliferated following initial encounter with the orally-derived antigen in MLNs (Fig. 4e, f). 
Abortive T cells proliferation prior to tolerization has already been documented following oral-
tolerization 47, 48. We further followed the fate of Ova-specific CD8+ T cells upon Ova re-encounter 
in the context of gene therapy. We then showed that Ova-specific CD8+ T which expanded 
significantly in tolerized animals during the 7 days of Ova-feeding (Fig. 4e, f and 5c at day 0), 
declined rapidly after injection of AAV-Ova while they expanded dramatically in control animals 
(Fig. 5). Hence, CD8+ T cells that have encountered orally-derived antigen during the tolerization 
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phase are not only incapable to respond to the same antigen in the context of AAV-mediated gene 
transfer but are also rapidly induced to die. 
 
 The data reported herein provide the first proof-of-principle study indicating that oral-
tolerization represents a candidate approach to circumvent the bottleneck of the immune response 
directed toward the transgenic protein. Interestingly, protein of interest can be given 
prophylactically before AAV vector injection in patients who are immunologically naive to the 
transgene product, provided that they have never been sensitized by protein replacement therapy. 
Yet, production of large quantities of proteins that would be compatible with oral administration in 
humans may represent a challenge. Several production systems and/or method of vectorization can 
however be envisioned. For instance, transgenic probiotics can be administrated orally in mice and 
humans without any conspicuous side effect and can possibly be used to directly deliver proteins of 
interest in the gastrointestinal tract 49-51. Beside probiotics, transgenic plants represent an alternative 
low cost method for the production of proteins suitable for oral ingestion. Bioproduction in 
comestible plants simplify the production steps, eliminate the need of extensive purification, and 
allow the production of glycosylated proteins that are structurally and functionally closely related 
to the native protein 52, 53. Moreover, protein synthetized in plants are naturally bioencapsulated, 
ensuring their protection from gastric and proteolytic degradation and facilitate their delivery in the 
gut where plants are digested by the action of commensal bacteria. In addition, protein of interest 
can be fused to transmucosal carriers that can facilitate their delivery across intestinal epithelium. 
Plant-based oral tolerance has been recently illustrated in a murine model of hemophilia where 
prophylactic oral administration of the transplastomic plant expressing recombinant factor IX (F.IX) 
protein fused to the cholera toxin carrier B was demonstrated to inhibit antibodies formation in the 
context of protein replacement therapy 54-56. In the same line, the present results further illustrate the 
efficacy of a prophylactic oral-tolerization protocol in the context of AAV-based gene therapy to 
promote specific and long-term tolerance to the transgenic protein coded by the vector.  
 
 Prevention of immune sensitization, rather than control of already primed immune responses, 
may arguably be more efficient and may partly explain the limited success of oral-tolerization 
strategies in autoimmune diseases. Consistently, we showed that oral-tolerization is efficient to 
prevent primary immune responses elicited by AAV vectors but not secondary/memory immune 
responses (Fig. 6a-d). Interestingly, oral-tolerization was still effective when initiated at the same 
time as AAV-vectors injections, possibly in relation with the known delay necessary for transgene 
expression when using single-stranded DNA AAV vectors. We thus believe that the present study 
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pave the way for further investigations in larger animals of prophylactic, rather than interventional, 
oral-tolerization protocols to prevent immune responses against transgenic proteins and/or against 
the proteins of the vector. Such oral-tolerization protocol could be used in combination with oral 
rapamycin and/or low-dose i.v. injection of the protein of interest, that have been shown to prevent 
and reverse inhibitory antibodies formation elicited by i.m. injection of AAV-F.IX in an animal 
model of hemophilia 57. Also, given the recently characterized immunoregulatory properties of 
probiotics, oral administration of modified probiotics expressing the proteins of interest may further 
improve oral-tolerization protocols by facilitating the tolerization against multiple proteins at the 
same time and may thus deserve further investigation in the field of gene therapy.  
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Materials and methods 
 
Mice  
Female C57BL/6Rj (B6) mice were obtained from Janvier Labs. TCR-transgenic OT-I mice, and 
congenic B6 mice expressing the CD45.1 (Ly5.1) allelic marker were obtained from Charles River 
Laboratories. [OT-IxLy5.1]F1 mice were used as a source of anti-Ova TCR-transgenic CD8+ T cells 
expressing the CD45.1 marker. Mice were housed in a specific pathogen-free barrier facility and 
were between 8–12 weeks of age at beginning of the experiments.  
 
Plasmidic constructs, preparation of recombinant AAV vectors and muscles transduction 
The plasmidic construct used for the generation of a recombinant AAV2/1 vector, coding for soluble 
Ova (AAV-Ova), was kindly provided by Roland W. Herzog 5, 16. Recombinant AAV2/1-Ova 
vectors were generated using a standard helper-virus free transient transfection method and 
pseudotyped with AAV1 capsid proteins as described before 37, 38. Genome titers, expressed by 
equivalent vector genomes (vg), were evaluated by dot-blot hybridization and by qPCR. For muscle 
transduction, mice hind legs were shaved under anesthesia and titrated amounts of AAV-Ova 
vectors, (i.e., 3.5x109, 5×1010 or 1011 vg) were injected in each gastrocnemius muscles. In some 
experiments, mice received together with AAV-Ova (3.5x109 vg/mice), 10 µg of CpG ODNs 1826 
(Sigma-Aldrich) to mimic situations where vector administrations are associated with TLRs 
activation.   
 
Oral Ova protein administration 
Oral-tolerization was induced by offering to mice, ad libitum, for 7 consecutive days, a solution of 
1% Ova (Sigma-Aldrich, grade II) dissolved in their drinking water. This solution was freshly 
prepared each day. In some experiments, variation of this protocol were evaluated consisting of oral 
administration of the protein only for 5 days, or for 7 days at the reduced concentration of 0.1%. All 
these protocols similarly resulted in the complete prevention of cellular and humoral immune 
responses directed against Ova following i.m. injections of AAV-Ova vectors (data not shown). 
 
Mice immunization 
In some experiments, mice were pre-immunized 21 days before oral-tolerization. For that, 100 µg 
of Ova was emulsified in CFA and s.c. injected in their shaved back. In other experiments, mice 
were immunized after oral-tolerization with a highly immunogenic vaccine consisting of a live strain 
of Listeria monocytogenes expressing Ova (Lm-Ova), kindly provided by G. Lauvau 58. For that, 
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mice were injected i.v. with 106 cfu of titrated Lm-Ova preparations diluted in 100 µl of PBS as 
described previously 38, 40. 
 
Tumor model 
Mice injected 14 days before with AAV-Ova, were subcutaneously injected in their shaved flanks 
with 106 EL4-Ova (EG-7) tumor cells. Mice were then examined every other days and tumor 
development was monitored for 31 days using a digital caliper as described previously 38, 40. 
 
Adoptive T cell transfer 
Ova specific CD8+ T cells were obtained from the spleens of [OT-I x Ly5.1]F1 mice and purified 
by magnetic sorting using a CD8 negative isolation kit (Invitrogen). More than 93% of the purified 
cells displayed a CD3+CD8+Vα2+Vβ5+CD45.1+CD4-CD19- phenotype as assessed by flow 
cytometry. For in vivo proliferation assay, cells were stained with 20 μM Cell Proliferation Dye 
eFluor® 450 (eBiosciences) for 10 minutes and 105 washed cells were then adoptively transferred 
i.v. into each B6 recipient mice.  
 
Antibodies and flow cytometry 
Fluorochrome-conjugated antibodies were all obtained from eBioscience except for antibodies to 
Bcl-2, CD24, CD73, CD80, CD86 and IFNγ obtained from BD Biosciences, and anti-Nrp-1 from 
Biolegend. Intracellular Foxp3, Helios, Bcl-2, IL-10 staining were done using the Intracellular 
Fixation & Permeabilization kit (eBiosciences) 38, 40. PE-conjugated H-2Kb/Ova257-264 dextramers 
were used to detect CD8+ T cells that specifically recognize the immunodominant Ova257-264 peptide 
using the manufacturer's protocol (Immudex). Single-cell suspensions derived from spleen, lymph 
nodes or peripheral blood (PBL) were analyzed by flow cytometry using a FACSCanto-I or an 
LSRFortessa (BD Biosciences), and using FlowJo software (Tree Star).  
 
ELISA and ELISpot assays 
Quantification of soluble Ova concentration in serum and titration of anti-Ova IgG antibodies were 
performed by ELISA as previously described 37 . Anti-Ova IgG titers were defined as the dilution 
yielding the half-maximum optical density obtained with a positive control serum that was used 
throughout the all study. Titers were calculated using sigmoid curve fitting performed in Prism 
software (Graphpad). Enzyme-linked immunospot (ELISpot) assays were used to quantify the 
numbers of Ova-specific CD8+ or CD4+ T cells secreting IFNγ upon in vitro restimulation as 
previously described 37. For that, 2.5×105 to 105 splenocytes per well were cultured overnight in 
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RPMI medium in the presence of 10 μg/ml Ova257-264 or Ova323-339 peptides for detection of, 
respectively, MHC I or MHC II restricted cellular immune responses, or, with peptides 
SNYAKSANV, MIPQYGYL and PQYGYLTL for detection of anti-capsid AAV1 cellular immune 
responses. Cultures were stopped and treated according to manufacturer’s instructions (Diaclone). 
Number of spots in each well were analyzed with an ELISpot plate reader and a dedicated 
ImmunoSpots software (C.T.L.). 
 
Histology and immunofluorescence microscopy 
Whole gastrocnemius were snap-freeze in isopentane pre-cooled in liquid nitrogen. Transversally 
cryosectioned slices were either stained with hematoxylin and eosin (H&E) for histological 
evaluations or prepared for immunofluorescence. Briefly, muscles slices were fixed with 1% 
paraformaldehyde and incubated with flurochrome-conjugated anti-mouse CD8 (53-6.7) and anti-
CD3 (500A2) antibodies, obtained from eBiosciences. Nuclei were counterstained with DAPI. 
Slides were viewed with a Zeiss Axioplan 2 microscope, and data collected using Zeiss Apotome 
and Axiovision 4.1 software. 
 
Quantification of Ova cDNA and mRNA in transduced muscles  
Ova DNA and corresponding Ova mRNA were quantified from transduced muscles by real-time 
PCR using SYBR green Mastermix (Roche) in a final volume of 10 μl as described previously 37, 
38. All qPCRs were performed with a LightCycler 480 (Roche). The relative amount of Ova DNA 
or Ova mRNA were determined using a standard curve obtained after serial dilutions of a plasmidic 
construct coding for Ova, and normalized for each sample by the amount of Eef2.  
 
Statistical analysis 
All data are shown as mean values and error bars represent SEM. Non-parametric tests were used 
for statistical comparison between experimental groups using one-way ANOVA (Kruskall-Wallis 
tests). Unless otherwise stated, all the experiments have been repeated at least 3 times and 
illustrations shown here are representative of all experiments. Differences were considered 
statistically significant when p values were less than 0.05 (*), 0.01 (**) or 0.001 (***). All 
calculations were performed using the Prism software (Graphpad).  
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Figure Legends 
 
Figure 1. Oral-tolerization prevents immune responses directed against the transgenic 
protein. 
 (a) Protocol outline. B6 mice were given 1% of Ova, ad libitum, in drinking water during 7 days 
and then injected with AAV-Ova (5x1010 vg/mouse) in both gastrocnemius (n=5 per group). 
Immune responses were monitored between days 14 and 80 after injections. (b) Blood samples were 
collected 14 days post AAV-Ova transduction and percentage of Ova-specific CD8+ T cells was 
determined using H-2Kb/Ova257-264 dextramers staining and flow cytometry in control (ctrl) and 
tolerized (tol) mice. The representative flow cytometric panels shown here represent percentages of 
Ova-specific CD8+ T cells in the gated CD8+ population (c) Percentages of Ova-specific CD8+ T 
cells in the blood were determined at the indicated times points post AAV-Ova transduction. (d-e) 
Sera were collected at 80 days (d) or at the indicated time points (e) post AAV-Ova transduction 
and anti-Ova IgG titers were determined by ELISA. Curves represent optical density plotted against 
dilutions factors from data obtained at day 80 (d). The IgG titers correspond to the dilution yielding 
the half-maximum optical density obtained with a positive control serum used in all experiments 
(e). (f-g) At day 80, splenocytes were harvested and analyzed by ex vivo ELISpot assays for their 
capability to secrete IFNγ after restimulation with the Ova257-264 peptide. (f) Representative ELISpot 
data obtained with control and tolerized mice. (g) Average number of spot forming cell (SFC) per 
106 splenocytes obtained in control and tolerized group of mice (n=5/group). (h-i) 106 EG7 Ova-
bearing tumor cells were injected 14 days after AAV-Ova or PBS injections (n=5/group). Mice were 
monitored for tumor development (h) and tumor volume (i). 
 
Figure 2. Oral-tolerization prevents muscle infiltration by CD8+ T cells. 
 Mice were tolerized or not during 7 days with 1% Ova in drinking water and injected as before with 
AAV-Ova (5x1010 vg/mouse) in both gastrocnemius at day 0 (n=6 per group). Muscles were 
collected at the indicated times points post AAV-Ova injection. Muscle sections from control (a-c) 
and tolerized (d-f) mice were stained with hematoxylin and eosin to evaluate muscle histology and 
the overall level of mononuclear cell infiltration. Muscle sections from control (g-i) and tolerized 
(j-l) mice were analyzed by immunofluorescence after immunostaining with anti-CD3 (green) and 
anti-CD8 (red) antibodies and nucleus counterstaining with DAPI (blue). Scale bars represent 50 
μm and arrows in (a) and (b) show area containing infiltrating cells.  
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Figure 3. Oral-tolerization favors transgene long-term expression.  
AAV-Ova injected muscles were harvested at day 80 from tolerized or control mice and transgene 
persistence and expression were evaluated using qPCR and qRT-PCR. (a) Transgene persistence in 
transduced muscle was evaluated by quantification of Ova DNA by qPCR. (b) Transgene expression 
was evaluated by quantification of the corresponding Ova mRNA by qRT-PCR. Data were 
normalized against the level of Eef2 mRNA (arbitrary units). (c) Mean concentrations of Ova in the 
sera of tolerized and control mice were determined 18, 35 and 80 days after AAV-Ova injection by 
ELISA. 
 
Figure 4. Oral-tolerization induces abortive proliferation, expression of PD-1 and 
downregulation of Bcl-2 in adoptively transferred Ova-specific CD8+ T cells. 
 (a-b) Mice were orally-tolerized during 7 days with 1% Ova in drinking water and then injected 
i.v. with 106 pfu of a live strain of Listeria monocytogenes expressing Ova (Lm-Ova) (n=5/group). 
Blood samples were collected after infection to monitor the cellular levels of Ova-specific CD8+ T 
cells by flow cytometry. (a) Representative cytometric profiles obtained at day 10 post-infection 
were gated on the CD8+ population. (b) Percentage of anti-Ova CD8+ T cells 10 and 22 days post-
infection are shown. (c-h) 105 Ova-specific CD8+ T cells (OT-I CD45.1+), stained with a 
proliferation tracking dye, were adoptively transferred into CD45.2 congenic mice. Recipient mice 
were then orally-tolerized during 7 days and MLNs were harvested and analyzed by flow cytometry 
(n=5/group). (c) Representative cytometric profiles, gated on the CD8+ population, and (d) 
percentage of CD45.1+ cells in MLNs are shown. (e) Cytometric profiles representing the level of 
cell proliferation (dilution of the proliferation dye) and PD-1 expression on gated CD45.1+ cells. (f) 
Percentage of CD45.1+PD-1+ cells in the gated CD8+ cells and their proliferation index. (g) 
Cytometric profiles showing the expression of CD73 (top) and Bcl-2 (bottom) on the gated CD45.1+ 
cells. (h) Percentage of CD45.1+CD73+ cells (left) and mean fluorescence intensity of Bcl-2 staining 
(right). 
 
Figure 5. Oral-tolerization induces deletion of Ova-specific CD8+ T cells in the context of gene 
therapy. 
As in figure 4, 105 OT-I CD45.1+ cells were adoptively transferred into CD45.2 congenic recipient 
mice, which were then orally-tolerized during 7 days. At the end of the oral-tolerization protocol, 
mice were injected with AAV-Ova in both gastrocnemius (3.5x109 vg). Spleen, MLNs and draining 
lymph nodes (dLNs) were harvested for flow cytometry analysis (n=5/group). (a) Percentage of 
transferred CD45.1+ cells in the gated CD8+ population was evaluated in spleen and dLNs 10 days 
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post transduction. (b) In other groups of mice, percentage of transferred CD8+CD45.1+ cells was 
also evaluated in the blood at day 14 post-injection. (c) Total number of CD45.1+ transferred CD8+ 
cells was enumerated from the harvested pooled lymphoid organs (spleen, dLNs and MLNs) before 
AAV-Ova injection (at day 0) and 10 and 17 days thereafter. 
 
Figure 6. Oral-tolerization is very efficient to prophylactically prevent immune responses, but 
not to suppress already primed immune responses.  
(a-c) Mice were pre-immunized or not with CFA/Ova. Three weeks later, mice were orally-tolerized 
during 7 days with 1% Ova solubilized in their drinking water. At the end of the tolerization 
protocol, mice were transduced using 3.5x109 vg of AAV-Ova injected in both gastrocnemius. (a) 
CD8+ cellular immune responses were monitored by flow cytometry in pre-immunized and non-
pre-immunized groups by collecting blood samples 15 days after AAV-Ova injections. Bar graph 
represents the percentage of Ova-specific CD8+ T cells in each indicated groups. (b-c) 80 days after 
AAV-Ova injections, splenocytes were harvested and Ova-specific CD8+ (b) and CD4+ (c) immune 
responses were evaluated by ELISpot assays. (d) 80 days after AAV-Ova injections, sera were 
collected and anti-Ova IgG were titrated by ELISA. (e-g) Mice were orally-tolerized during 7 to 10 
days with 1% Ova in their drinking water either before (day -7 to 0), at the same time (day 0 to 10), 
or after (day 10 to 20) AAV-Ova injection. (e-f) Blood samples were collected 14 days (e) or 21 
days (f) post AAV-Ova transduction and the percentage of Ova-specific CD8+ T cells was 
determined using H-2Kb/Ova257-264 dextramers staining and flow cytometry in the indicated group 
of mice. (g) Transgene persistence and expression was evaluated by quantification of Ova mRNA 
by qRT-PCR in the indicated group of mice. Data are normalized against the level of Eef2 mRNA 
(arbitrary units). 
 
Supplemental Figure 1. Evaluation of oral-tolerization protocols differing in duration and 
antigen dose.  
(a-c) Mice (n=5 per group) were given 1% Ova in their drinking water for 7 days and were then 
injected with different vector doses: 1x1011 vg/mouse (a), 5x1010 vg/mouse (b) or 3.5x109 vg/mouse 
(c). Percentages of Ova-specific CD8+ T cells were determined by flow cytometry in control and 
tolerized mice at day 14 (a-c). (d-f) Mice (n=6 per group) were given 1% Ova in their drinking 
water for 5 days and were then injected with 1x1011 vg/mouse. (d) Blood samples were collected 
and Ova-specific CD8+ T cells were determined by flow cytometry at day 14. (e-f) Sera were 
collected 80 days after AAV-injection and anti-Ova IgG titers (e) and mean concentrations of Ova 
in sera (f) were determined by ELISA. (g) Mice (n=5 per group) were given with 0.1% Ova in their 
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drinking water for 7 days and were then injected with 3.5x109 vg/mouse. Ova-specific CD8+ T cells 
in blood were determined 14 days after AAV-injection by flow cytometry. 
 
Supplemental Figure 2. Oral-tolerization inhibits immune responses even in situations where 
AAV vector administration is associated with concomitant TLR9 activation. 
B6 mice (n=7 per group) were given 1% Ova in their drinking water for 7 days and were then 
injected with AAV-Ova (3.5x109 vg/mouse) contaminated with CpG-ODNs 1826 (10 µg/mouse) in 
their gastrocnemius muscles. Immune responses were monitored between days 15 and 40 post vector 
injections. (a) Blood samples were collected at different time points and percentages of Ova-specific 
CD8+ T cells were determined by flow cytometry in untolerized control mice (CpG) and in tolerized 
mice (CpG tol). (b) Sera were collected at days 21 and 39 post AAV-injections and anti-Ova IgG 
titers were determined by ELISA. (c) Splenocytes were harvested at day 40 and analyzed for IFNγ 
secretion after ex vivo restimulation with MHC I restricted Ova257-264 peptide, MHC II restricted 
Ova323-339 peptide, or with MHC I restricted AAV1 capsid peptides. (d) Transduced muscles were 
harvested at day 40 and Ova mRNA were quantified by qRT-PCR. (e) Mean Ova concentrations in 
sera were analyzed by ELISA 39 days post AAV-injections. 
 
Supplemental Figure 3. Oral-tolerization is not associated with obvious modification of 
immune cell subsets in mesenteric lymph nodes.  
Mesenteric lymph nodes (MLNs) were harvested at the end of the oral-tolerization protocol, (i.e. at 
day 0), and cellular subsets were analyzed by flow cytometry. (a) Percentage of each indicated 
leukocyte population was determined in control and tolerized mice by flow cytometry. (b) 
Percentage of gated CD11c+ DCs subsets expressing CD103+ or expressing both CD103+ and 
CD24+. (c) Percentage of CD19highCD86+IL-10+ (considered as regulatory B10 cells) and level of 
expression of IL-10 were assessed by intracellular staining. Percentage of B10 cells were found to 
be equivalent in the two groups of mice (12.48% ±2.3 in control mice and 10.57% ±3.8 in tolerized 
animal) as were their levels of IL-10 expression, represented here by the mean fluorescence intensity 
(MFI) of IL-10 intracellular staining. (d-h) CD4+Foxp3+ Tregs from MLNs were analyzed for 
expression of Helios and Nrp-1 markers as well as for CTLA-4, Foxp3 and CD25 contents. (d) 
Representative cytometric profiles and (e) percentage of Tregs subsets according to the expression 
of Helios and Nrp-1 are shown. (f-h) Mean fluorescence intensity (MFI) of CTLA-4 (f), Foxp3 (g) 
and CD25 (h) staining in the gated CD4+Foxp3+ Tregs population is shown. (i) No significant 
differences were found neither on the proportion of CD4+CD25-LAG-3+ cells (3.6% ±0.5 in control 
vs. 2.4% ±0.2 in tolerized animals) nor in the mean expression level of LAG-3.  
 25 
 
Supplemental Figure 4. Tregs depletion/inactivation is not sufficient to abrogate oral 
tolerance.  
As treatment with the anti-CD25 antibody (PC-61) is known to inactivate Tregs suppressive 
functions without necessarily depleting them 59, three strategies were evaluated to inactivate and 
deplete Tregs in vivo: two injections of PC-61 anti-CD25 antibody (days - 3 and - 1 before AAV 
injection) 40, injection of 60 mg of NAD alone 40, or the combination of both treatments. (a) 
Cytometric profiles gated on CD4+ cells showing percentage of Foxp3+ and CD25+ cells following 
these treatments. (b) Total number of CD4+Foxp3+ cells in blood after treatment with PC-61 and/or 
NAD. Experiments were performed three times, except for NAD treatment that has been extensively 
studied in our previous study 40 and was tested here only once. (c-e) Tregs were inactivated/depleted 
in vivo by co-treatment with two injections of PC-61 (days - 3 and - 1 before AAV injection) and 
one injection of NAD at the end of the oral-tolerization protocol (day - 1) before injection with 
AAV-Ova (5x1010 vg) at day 0 (n=5-7). Blood was collected at the indicated time points to monitor 
the cellular Ova-specific cytotoxic T cell response by flow cytometry. Representative flow 
cytometry profiles at day 14 on CD8+ gated cells (c) and bar graph (d) representing the percentage 
of Ova-specific CD8+ T cells 14 to 42 days after vector injection on the different groups of mice are 
shown. (e) Sera were collected at day 49 to assess the humoral anti-Ova antibody response by 
ELISA.   
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